测试版
试验雷达 AI
临床试验 NCT06623669 (MORPH-III) 针对慢性疼痛,骨关节炎,Obesity and Overweight,Inactivity目前招募中。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情,或在此提出任何问题。
一个试验符合筛选条件
卡片视图

A Mobile Intervention to Reduce Pain and Improve Health-III (MORPH-III)

招募中
临床试验详情主要以英语提供。然而,试验雷达 AI可以提供帮助!只需点击“解释临床试验”即可查看和讨论您选择的语言的试验信息。
临床试验NCT06623669 (MORPH-III)旨在研究治疗,主要针对慢性疼痛,骨关节炎,Obesity and Overweight,Inactivity。这是一项II期 (第二期) 干预性研究试验,目前试验状态为招募中。试验始于2025年8月15日,计划招募200名患者。该研究由维克森林大学主导,预计于2029年8月31日完成。试验数据来源于ClinicalTrials.gov,最后更新时间为2025年8月1日
简要概括
The experience of chronic pain powerfully and negatively affects quality of life and functional independence in aging. Unfortunately, while as many as three in four older adults experience chronic pain, few have access to effective non-pharmacological pain management strategies. Participating in regular physical activity, avoiding sustained sitting, and maintaining a healthy weight are important and interrelated lifestyle inputs to chronic pain, and socially rich behavioral interventions informed by contemporary theories of behavior change appear important for engaging in activity and healthy eating in the long term. Our group has demonstrated in a series of Stage I trials that a group-mediated behavioral intervention combining dietary behavior change and a physical activity program focused on moving often throughout the day contributes to meaningful weight loss, and lasting weight maintenance, with pilot data suggesting this may contribute to improved pain, physical function, and health-related quality of life among older adults with chronic pain. As these were NIH Stage I trials, there are several important gaps to be addressed in the present trial: (1) both studies of chronic pain recruited small samples and were 12 weeks in duration, limiting our ability to establish efficacy and the durability of changes to activity, HRQOL, and pain outcomes; (2) participants included anyone with chronic pain, regardless of pain type, a likely contributor to heterogeneous pain intensity and interference findings; and (3) the investigators have yet to examine behavioral maintenance.

The overarching goal of the proposed Stage II "mobile intervention to reduce pain and improve health-III (MORPH-III)" is to establish the efficacy of the intervention for enhancing physical activity via steps (primary), and for reducing pain interference and body weight while enhancing physical function (secondary) among older adults with chronic knee or hip osteoarthritic (OA) pain. The investigators will recruit 200 older adults with knee or hip osteoarthritic pain to engage in a 6-month remotely delivered intervention comprising weekly group or individual intervention meetings plus brief individual goal-setting coaching calls. This will be followed by a 12-month no-contact maintenance period, where participants will attempt to sustain behavioral goals on their own.

The Specific Aims are:

Specific Aim 1: To examine the impact of MORPH on ActivPAL-assessed daily steps relative to an enhanced usual care control. Hypotheses: MORPH will significantly increase steps relative to control at month 6.

Specific Aim 2: To examine the impact of MORPH on pain interference, change in body weight, and physical function relative to the enhanced usual care control. Hypotheses: MORPH will result in significant reductions in pain interference and body weight and improvement in physical function relative to control at month 6.

Exploratory Aims: Aim 1: To investigate the impact of the MORPH intervention on steps, weight change, pain interference, and physical function at month 18. Aim 2: If the MORPH intervention results in reduced pain interference at 6 and/or 18 months, the investigators will examine the extent to which 6-month change in steps, weight, pain self-efficacy, and catastrophizing mediate change in interference at 6 and/or 18 months.

官方标题

A Mobile Intervention to Reduce Pain and Improve Health-III

疾病
慢性疼痛骨关节炎Obesity and OverweightInactivity
其他研究标识符
NCT编号
实际开始日期
2025-08-15
最近更新发布
2025-08-01
预计完成日期
2029-08-31
计划入组人数
200
研究类型
干预性研究
试验分期 (阶段)
II期 (第二期)
试验状态
招募中
关键词
Digital health
Randomized Trial
Physical Activity
Weight Loss
Aging
主要目的
治疗方法
分配方式
随机
干预模型
平行
盲法
单盲
试验组/干预措施
参与者组/试验组干预措施/治疗方法
实验性MORPH
MORPH participants will attend one weekly group-mediated session alongside a group of their peers plus individual coaching calls. Participants will aim to increase daily steps by moving often throughout the day, using an activity monitor and mHealth app to view feedback and set goals. Participants will also aim to weight via healthy eating while reducing daily calories by \~400kcal/day below weight maintenance needs to achieve approximately 6% weight loss in 6 months and 10% over 18 months.
MORPH
A remote behavioral intervention combining coaching and digital health tools to improve diet and activity behaviors.
阳性对照Measurement Only
Measurement-only participants will receive an activity monitor and wireless weight scale to account for the effect of these self-monitoring technologies and activity behavior.
Measurement ONLY
This intervention entails receipt of a body weight scale and wearable activity monitor.
主要终点
结果指标度量标准描述时间框架
Daily steps
Daily steps measured over one week via the ActivPAL accelerometer
Baseline, after 6 months of intervention, after 18 months of intervention
次要终点
结果指标度量标准描述时间框架
Pain Interference
Measured via questionnaire: the Patient-Reported Outcomes Measurement Information System (PROMIS) 8-item pain interference scale, which produces a t-score such that the population mean is a 50 with a standard deviation of 10; higher scores indicate higher interference.
Baseline, after 6 months of intervention, after 18 months of intervention
Body weight
Measured via the BodyTrace wireless body weight scale
From the start of the intervention through month 18.
30-second chair stand
Measured via in-home chair stand task.
Baseline, after 6 months of intervention, after 18 months of intervention
Gait speed
Measured via in-home test: 4-meter habitual gait speed
Baseline, after 6 months of intervention, after 18 months of intervention
资格标准

适龄参与研究
老年人
最低年龄要求
65 Years
适龄性别
全部
  • Aged 65+ years
  • Body mass index of 30-45 kg/m2 or >45 kg/m2 with physician's approval
  • No loss or gain of more than 5% body mass in previous 6 months
  • Presence of knee or hip osteoarthritis as ascertained via the Roux questionnaire
  • Independently living
  • Low active (i.e., not participating in regular resistance training and/or >20 mins/day of aerobic exercise on more than 2 days/week in past 3 months as ascertained via a modified CHAMPS questionnaire)
  • Have no contraindication for safe and optimal participation in exercise based on EASY screening
  • Not currently using a weight loss medication
  • Approved for participation by medical director
  • Willing to provide informed consent and agree to all study procedures and assessments.

  • Reside in skilled nursing facility, rehab or assisted living environment
  • History of pharmacologic treatment for a psychiatric disorder other than depression/anxiety within past year
  • Current untreated and/or unstable clinical depression or anxiety (Patient Health Questionnaire (PHQ-9) >15)
  • Hospitalization for psychiatric event within past year prior to screening
  • History of mild cognitive impairment or dementia
  • Cognitive impairment (<32) on Modified Telephone Interview for Cognitive Status survey (TICS-M)
  • Hearing or visual impairment that would preclude use of the videoconferencing software
  • Severe arthritis or other musculoskeletal disorder that is a contraindication for safe walking
  • Presently undergoing treatment for orthopedic fracture
  • Currently using a weight loss medication
  • Contraindication based on EASY screening without physician approval.
  • Joint replacement or other orthopedic surgery in past 6 months
  • Joint replacement or other orthopedic surgery planned in next 18 months
  • Have a diagnosis of uncontrolled hypertension; current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease other than asthma or COPD, any disease requiring oxygen use, neurological or hematological disease; cancer requiring current treatment, except non-melanoma skin cancers; kidney failure requiring dialysis; have a Katz ADL disability; or engage in heavy alcohol use >14 drinks/week.
  • Current participation in other research study with a prospective intervention
  • Unable/unwilling to commit to study protocol, including random assignment and use of technology tools
  • Unable/unwilling to attend three virtual testing appointments
研究责任方
Jason Fanning, 主要研究者, Assistant Professor, Wake Forest University
研究中心联系人
联系人: Deja O Dobson, MS, 3367585042, [email protected]
联系人: Jason Fanning, PhD, 3367585042, [email protected]
1 位于 1 个国家/地区的研究中心

North Carolina

Wake Forest University, Winston-Salem, North Carolina, 27109, United States
Deja Dobson, 联系人, 336-758-6677, [email protected]
招募中